The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction

Inclusion Criteria

• •Patients diagnosed with HCM according to the 2023 Chinese Guidelines for the Diagnosis and Treatment of Adult Hypertrophic Cardiomyopathy, meeting one of the following:
• •1. Left ventricular wall thickness ≥15 mm at end-diastole in any segment as assessed by echocardiography or cardiac magnetic resonance imaging (CMR);
• •2. Left ventricular wall thickness ≥13 mm in individuals with a confirmed pathogenic gene mutation or in genetically affected family members;
• •3. Exclusion of other cardiovascular, systemic, or metabolic disorders that may cause ventricular hypertrophy.
• •* Symptomatic non-outflow tract obstructive HCM patients (meeting criterion a and at least one of b or c):
• •<!-- -->
• •1. Presence of clinical symptoms such as dyspnea, chest pain, dizziness, palpitations, or syncope, with New York Heart Association (NYHA) functional class II-III;
• •2. Maximal pressure gradient (PGmax) \>30 mmHg in the mid-ventricle under resting or Valsalva maneuver as assessed by echocardiography;
• •3. PGmax \>30 mmHg in the apical region under resting or Valsalva maneuver on echocardiography.
• •③Ability to provide written informed consent (ICF) and any required privacy authorization prior to study enrollment.